• Image Gallery
    • Onsite Information
    • Welcome Message
    • Venue & City Information
    • Visa Requirements
    • Call for Volunteers
    • First Time WCLC Attendees
    • Future WCLC
    • Important Dates
    • Press & Media
    • Press Conference Webcast
    • Registration
    • Accommodation
    • Scientific Program
    • Program Committee
    • Program at a Glance
    • Interactive Breakfast Sessions
    • Workshops
    • Networking Opportunities
    • CME Information
    • Disclosures
    • Sponsorship
    • Exhibit
    • Exhibitor Kit
    • Industry Symposia
    • Advisory Board & Ancillary Meetings
    • Information for Abstract Presenters
    • Call for Abstracts
    • Travel Awards
    • IASLC International Mentorship Program
MENU
  • Join Mailing List
  • IASLC.org
  • Contact Us
  • Information
    • Image Gallery
    • Onsite Information
    • Welcome Message
    • Venue & City Information
    • Visa Requirements
    • Call for Volunteers
    • First Time WCLC Attendees
    • Future WCLC
    • Important Dates
  • Conference Program
    • Scientific Program
    • Program Committee
    • Program at a Glance
    • Interactive Breakfast Sessions
    • Workshops
    • Networking Opportunities
    • CME Information
    • Disclosures
  • Abstracts &
    Scholarship
    • Information for Abstract Presenters
    • Call for Abstracts
    • Travel Awards
    • IASLC International Mentorship Program
  • Sponsorship &
    Exhibits
    • Sponsorship
    • Exhibits
    • Exhibitor Kit
    • Exhibit Showcase Sessions
    • Industry Symposia
    • Advisory Board & Ancillary Meetings
  • Registration &
    Accommodation
    • Registration
    • Accommodation
  • Press & Media
    • Press & Media
    • Press Conference Webcast
  • Join Mailing List
  • IASLC.org
  • Contact Us
  • #WCLC19
  • Facebook
  • Twitter
  • Linkedin
  • Instagram
  • Youtube
Conquering Thoracic Cancers Worldwide
  • Information
    • Image Gallery
    • Onsite Information
    • Welcome Message
    • Venue & City Information
    • Visa Requirements
    • Call for Volunteers
    • First Time WCLC Attendees
    • Future WCLC
    • Important Dates
  • Conference Program
    • Scientific Program
    • Program Committee
    • Program at a Glance
    • Interactive Breakfast Sessions
    • Workshops
    • Networking Opportunities
    • CME Information
    • Disclosures
  • Abstracts &
    Scholarship
    • Information for Abstract Presenters
    • Call for Abstracts
    • Travel Awards
    • IASLC International Mentorship Program
  • Sponsorship &
    Exhibits
    • Sponsorship
    • Exhibits
    • Exhibitor Kit
    • Exhibit Showcase Sessions
    • Industry Symposia
    • Advisory Board & Ancillary Meetings
  • Registration &
    Accommodation
    • Registration
    • Accommodation
  • Press & Media
    • Press & Media
    • Press Conference Webcast
Get Tickets!

PRESS & MEDIA

  • Press & Media
  • Press Conference Webcast

Tweets by IASLC

We welcome media to attend the WCLC in person and we provide a media workroom and daily press conferences/media availability events. To book a room, please see our receptionist outside of the Press and Media office.

Press Program (PDF)

Press Conference - Live Webcast

Saturday, September 7th Press Briefing – 16:00-17:30, in front of mobile CT unit just outside plenary hall

Moderator: Dave Mesko

  • Welcome from co-chairs, R. Rami-Porta and T. Rosell
  • 20th WCLC highlights, include infographic. P. Bunn
  • STARS Program Announcement, STARS winner (C. Egwuenu), mentor (U.Basu Roy) and surgeon (B. Stiles)
  • IASLC Molecular Testing Survey, M. Smeltzer
  • IASLC Tobacco Declaration J. Jassem
  • Lung Ambition Alliance, G. Scagliotti with IASLC, AstraZeneca, GLCC and Guardant
Saturday Summary Press Release
  • Recipients Chosen for STARS Program for IASLC 20th World Conference on Lung Cancer
  • Lung Ambition Alliance unveils new initiatives to address lung cancer survival at the World Conference on Lung Cancer
  • Knowledge of Molecular Testing for Lung Cancer Strong but Not Universal
  • Tobacco Cessation After Cancer Diagnosis: Declaration from the IASLC


Sunday, Sept. 8th Press Briefing – 09:45-10:30

Moderator: Enriqueta Felip

  • Summary of day’s plenary (5 mins) and any key highlights/themes – E. Felip
  • Announcement of JTO Clinical and Research Reports -- A. Adjei
  • Phase 1 Study of Safety, Tolerability, P­­K and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC -- R. Govindan
  • Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial -- N. Rizvi
  • CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC -- F. Barlesi
  • Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC -- M. Garassino
  • KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC -- C. Langer
Sunday Summary Press Release
  • Nivolumab combined with ipilimumab safe as first-line therapy for lung cancer patients with co morbid diseases (Abstract)
  • New KEYNOTE 021 Data Shows No Association with Tumor Mutational Burden   (Abstract)
  • KEYNOTE 189: Tumor Mutational Burden Not Significantly Associated with Efficacy of Pembrolizumab  (Abstract)
  • Phase 1 Study Shows Novel KRAS Inhibitor Well Tolerated by Patients with Adenocarcinoma and Non-Small Cell Lung Cancer (Abstract)
  • Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial  (Abstract)
  • Journal of Thoracic Oncology Announces New Journal at World Conference on Lung Cancer
Sunday Summary Non-Press Briefing for Consideration - Click Here

 

Monday, Sept 9th (Presidential Symposium Press Briefing) – 10:15-11:00

Moderator: Giorgio Scagliotti

  • Summary of day’s plenary (5 mins) and any key highlights/themes – G. Scagliotti
  • Lung Cancer Screen Selection by USPSTF Versus PLCOm2012 Criteria – Interim ILST Finding -- S. Lam
  • Early Detection of Cancer of the Lung Scotland (ECLS): Trial Results -- F. Sullivan
  • Blood MicroRNA and LDCT Reduce Unnecessary LDCT Repeats in Lung Cancer Screening: Results of Prospective BioMILD -- U. Pastorino
  • In Hospital Clinical Efficacy, Safety and Oncologic Outcomes from VIOLET: A UK Multi-Centre RCT of VATS Versus Open Lobectomy for Lung Cancer -- E. Lim
  • Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers -- A. Drilon
  • National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC) -- G. Middleton
  • Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study -- L. Paz-Ares
Monday Summary Press Release
  • BioMILD Trial Demonstrates Lung Cancer Screening Using MicroRNA Blood Test Enhances Prevention Effort
  • Durvalumab combined with chemotherapy improves overall survival in patients with extensive lung -stage cancer; First-line treatment reduces mortality risk by 27 percent
  • Scottish Study Demonstrates that Autoantibody Test Followed By CT Imaging May Reduce Lung Cancer Mortality
  • Lung cancer screening model favored in Europe detects more cancers than one preferred in the United States
  • Registrational Data from LIBRETTO-001 Trial Demonstrate Compelling and Durable Activity of Selpercatinib (LOXO-292) in RET Fusion-Positive Lung Cancer
  • National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Video Assisted lung surgery reduces complications and hospital stays compared to open surgery


Tuesday, Sept 10th Press Briefing – 10:45-11:30

Moderator: Toni Rosell

  • Summary of day’s plenary (5 mins) and any key highlights/themes – T. Rosell
  • KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer -- M. Reck
  • IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC -- F. Cappuzzo
  • Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC-- S. Gettinger
  • Challenges in Lung Cancer Clinical Trials: A European Perspective -- A.M. Baird
  • PL 03: Establishing a Nurse Led Follow-Up Service for Patients With Resected Early Stage Lung Cancer -- J. Mitchell
Tuesday Summary Press Release
  • Europeans Face Significant Challenges to Participate in Lung Cancer Clinical Trials (Abstract)
  • Patients Taking Nivolumab Experience Five-Fold Increase in Overall Survival Compared to Chemotherapy (Abstract)
  • KEYNOTE-024 Three-Year Survival Update: Pembrolizumab Effective as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer (Abstract)
  • IMpower131: Final Overall Survival Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC (Abstract)

 

Sunday Press Releases for Consideration

  • Randomized Clinical Trial with Computer Assisted Diagnosis (CAD) Versus Radiologist as First Reader of Lung Screening LDCT -- R. Yuan
  • Evaluation of the Clinical Utility of the PanCan, EU-NELSON and Lung-RADS Protocols for Management of Screen Detected Lung Nodules at Baseline -- R. Myers
  • Transforming the Patient Experience in Lung Cancer Through the Use of Clinical Nurse Specialist Virtual Clinics - The Liverpool Experience -- A.V. McIver (Sunday)

Monday Press Releases for Consideration

  • Patient Knowledge and Expectations Related to Return of Genomic Results in the Lung-MAP (SWOG 1400) Biomarker-Driven Clinical Trial -- Roth
  • Lung Cancer as a Second Primary Malignancy Among Women with Breast Cancer: The Role of Hormone Replacement and Smoking -- J. Bodor
  • The Role of Simulation Modeling in Shaping Lung Cancer Screening Policies in the US and Elsewhere -- Meza
  • Residential Radon, Smoking and Lung Cancer Risk. A Case-Control Study in a Radon Prone Area -- A. Ruano-Ravina
  • Opt-Out Smoking Cessation Program in Lung Cancer Screening Provides Excellent Quit Rates -- R. Myers
  • Quality of Life (QoL) Analysis in Lung Cancer: A Systematic Review of Phase III Trials Published Between 2012 and 2018 -- M.L. Reale

Tuesday Press Releases For Consideration:

  • Global Quantitative Mass Spectrometry Reveals Potential Novel Actionable Targets in Thymic Epithelial Tumors (TET) -- X. Zhang1
  • Clinical Rationale and Preclinical Evidence for Chimeric Antigen Receptor (CAR) T Cell Therapy Clinical Trial in KRAS-Mutant Lung Cancer -- Minehart
  • Challenging Negative Stereotypes Around Lung Cancer in Ireland -- A.M. Baird
  • NADIM Study: Updated Clinical Research and Outcome -- B. Sepesi
  • Closing remarks/conference highlights
Registration and Media Requirements

Press and Media registration now open!

Register Now

Eligibility

  • Companies or organizations producing publications, videos and other products intended for marketing, advertising, financial analysis or public relations purposes may not register to attend the meeting as media. This includes any organization that intends to sell or distribute video recorded at the WCLC for monetary gain. Any organization filming video is required to use either the official conference backdrop or a co-branded backdrop (include the IASLC logo). Any organization that misrepresents itself in regard to this manner will face sanctions and possible other actions, including confiscation of media credentials and dismissal from the meeting.
  • Financial analysts; sales, advertising or marketing representatives; book publishers and book authors may not register as media, but are welcome to register as regular attendees.
  • Public relations personnel and individuals from communications, print and online promotion services should register as a regular attendee (not as media).
  • Media are welcome to attend all general admission Scientific and Educational Sessions. These sessions may NOT be filmed on video. Ticketed sessions, such as "Interactive Breakfast Sessions”, are not open to media.

All media representatives are required to pre-register for the meeting and must be credentialed by the IASLC before being officially registered.

Journalists, including photographers, must work exclusively for the outlet for which they are credentialed (exceptions for freelance journalists are detailed below). Journalists who use their media privileges to work for non-credentialed organizations will have their privileges revoked. Journalists are required to complete the media online pre-registration form and submit the following:

  • A letter of assignment on the letterhead of the news organization being represented.
  • A photocopy of official press credentials, such a press card issued by a recognized journalists’ association or a government-sanctioned press organization (IASLC does not recognize press cards issued by web-based organizations such as IFNM) and/or a business card issued by a recognized news organization.

Freelance journalists including photographers may work for multiple publications, as long as they confirm in advance that those publications are eligible for media registration. Freelance journalists must submit the following:

  • A letter of assignment on the letterhead of the news organization being represented.
  • A recent copy of the publication (a mailed copy, link to the publication’s website or a photocopy of a cover/issue published within the past 6 months).
Media Policies

IASLC Press & Embargo Policies

Please read carefully as these policies have been updated for 2019, including:

  1. Abstract Embargo
  2. Press Release Embargo
  3. Social Media
  4. Interview
  5. Video, Photography and Audio Recording
  6. Live Coverage
  7. Presentation Slides and Poster Release
  8. Media List

Abstract Embargo Policy

Titles for all presentations will be available online at 17:00 EST on Wednesday, August 21, 2019.

Abstracts selected for inclusion in the WCLC press program will be kept under embargo until either the time of the presentation or the beginning of the WCLC press conference in which it is presented, whichever comes first. All abstracts covered in the WCLC press program will receive a press release. All other abstracts will be made will be available online on at 17:00 EST on Wednesday, August 21, 2019, in conjunction with the release of the Virtual Meeting.

Registrants will receive in their onsite registration material a custom URL link where all current WCLC2019 press materials will reside.
All abstracts, including those presented in the press program, will be published in the Journal of Thoracic Oncology in October 2019.

Press Release Policy

Press releases that feature data or events involving the WCLC should include the full name of the meeting, specifically: IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. Further, we respectfully request that the release include the official conference hashtag: #WCLC19. To learn more, please visit www.iaslc.org.

The IASLC develops press releases for presentations that are selected for the press program. These are to be released at the time the presentation begins or the press conference for that day begins, whichever comes first. Any organization or company issuing a press release about a presentation scheduled for the WCLC press program are asked to hold their releases until after the official IASLC release. If a presentation is selected for the WCLC press program, its content is embargoed until (1) the presentation begins or (2) the press conference for that day begins, whichever comes first. The IASLC welcomes the opportunity to collaborate on a press release for those abstracts selected for the WCLC press program.

For presentations not selected for the WCLC press program, the embargo lifts on September 5 at 17:00 EST.

Social Media Policy

Organizations may use social media to disseminate news and information regarding abstracts being presented at the WCLC. All information distributed through social media channels must adhere to the IASLC's embargo policy. Please use the IASLC's World Conference hashtag, #WCLC19 in any social media posts. Members of the media are permitted to photograph and transmit/share on any social media platform any presentation's slides without approval from the presenter and/or the IASLC unless explicitly forbidden. However, authors retain the copyright to their full slide presentations and all copyright laws apply to the reproduction, distribution and/or publication of slides. Representatives from academic institutions are permitted to share slides. Only non-flash photography of slide presentations is allowed.

Interview Policies

All interviews outside of press conferences must be arranged in advance with interviewees and must take place in IASLC approved and designated rooms, with an IASLC meeting backdrop. No last-minute or hallway interviews are permitted anywhere inside the conference facility. IASLC staff are available to help schedule interviews and a limited number of designated interview rooms are available, complimentary to credentialed media and may be scheduled for up to two hours. Sign up is required. For questions, please see the IASLC staff in the Media Room.

Media organizations filming a large amount of video content must contact the IASLC in advance (CMartin at DavidJamesGoup.com) and must meet the following requirements:

  1. All filming must take place in one designated spot (contact the IASLC for that location).
  2. No filming of sessions is allowed.
  3. All filming must be done in front of a backdrop which includes any of the below linked images of the IASLC logo. This may be co-branded to have your logo as well, as long as the IASLC logo is visible in the final footage.
    1. Logo 1
    2. Logo 2
    3. Logo 3
  4. All filming must include the official name of the conference “IASLC 2019 World Conference on Lung Cancer” in the questions asked of the interviewees, and acknowledgement must be given to the fact that the interview was conducted at the WCLC.
  5. Any footage placed on your website must include a reference to the IASLC World Conference on Lung Cancer.
  6. If possible, you may also include the conference hashtag: #WCLC19.

Video, Photography and Audio Recording Policy

Photography, videotaping and audio recording are allowed for news coverage only in the following areas/events:

  • Press Conferences/Media Availability
  • Interview rooms
  • Other designated locations (with IASLC approval)
  • Recording in common areas requires permission and/or an IASLC staff escort

Live Coverage Policy

We welcome live coverage of the event, and please contact us ahead of time to arrange this. An authorized representative of any press vehicle requiring electrical service or external cabling must be available to coordinate logistical details with IASLC. Live coverage is restricted to designated areas or an area approved by IASLC staff and is on a first-come, first-served basis.

Presentation Slides and Poster Release Policy

All presentation slides including audio or video recordings as well as the electronic poster files will be released in the virtual meeting within 24 hours after the presentation but only after the talk or the poster has been presented at the Conference.

Organizations may use social media to disseminate news and information regarding abstracts being presented at the WCLC. All information distributed through social media channels must adhere to the IASLC's embargo policy. Please use the IASLC's World Conference hashtag, #WCLC19 in any social media posts. Members of the media are permitted to photograph or record and transmit/share on any social media platform any presentation's slides without approval from the presenter and/or the IASLC unless explicitly forbidden. However, authors retain the copyright to their full slide presentations and all copyright laws apply to the reproduction, distribution and/or publication of slides. Representatives from academic institutions are permitted to share slides. Only non-flash photography of slide presentations is allowed.

Media List Policy

The IASLC does not release media lists for the IASLC World Conference on Lung Cancer.

Interview Rooms Available for Booking

Interview Rooms Available for Booking

Book Media Interview Room

All interviews outside of press conferences must be arranged in advance with interviewees and must take place in the IASLC approved and designated rooms. No last-minute or hallway interviews are permitted anywhere inside the conference facility. IASLC staff are available to help schedule interviews and IASLC provides designated interview rooms. A limited number of interview rooms are available complimentary to credentialed media and may be scheduled with IASLC staff for up to two hours through below link. 

All other interested parties may request an interview room for a fee.

Reservations for an interview room will be available shortly.

Contact

For questions, please contact:
Chris Martin, VP Public Relations
David James Group
CMartin at DavidJamesGroup.com
+1.630.670.2745

Failure to comply with these policies may result in the immediate revocation of any privileges of the current WCLC and for future IASLC events.

The IASLC reserves the right to change these policies when needed without notice.



  • About IASLC

    Information

    Image Gallery
    Onsite Information
    Welcome Message
    Venue & City Information
    Visa Requirements
    Call for Volunteers
    First Time WCLC Attendees
    Future WCLC
    Important Dates

    Conference Program

    Scientific Program
    Program Committee
    Program at a Glance
    Interactive Breakfast Sessions
    Workshops
    Networking Opportunities

  • Abstracts & Scholarship

    Information for Abstract Presenters
    Call for Abstracts
    Travel Awards
    IASLC International Mentorship Program

    Sponsorship & Exhibits

    Sponsorship
    Exhibits
    Industry Symposia
    Advisory Board and Ancillary Meetings

    Registration & Accommodation

    Registration
    Accommodation

    Press & Media
    Contact Us

     

     

  • Stay Connected

    Keep up to date with Conference News & Alerts.
    Sign Up

     

    #WCLC19

© 2019 International Association for the Study of Lung Cancer – IASLC WCLC 2019 | Privacy Policy

Conference Newsletter
Subscribe to the Newsletter to receive important information about the upcoming Conference.
Thank you! We look forward to connecting soon.
Click here to close this window
Whoops, looks like there was an issue with one of the fields above - please review above.
X